The FDA is approving new oncology drugs & indications at a rapid pace, making it nearly unsustainable for clinicians to keep current with the ever-changing landscape of cancer treatment. However, we must keep current with the data in order to identify when new therapeutic options are in the patient’s best interest to help afford them a better outcome.

The following article is part of a quarterly series highlighting new oncology FDA approvals. Here you will find information surrounding these novel approvals, including trial details, dosing, pertinent toxicity, drug cost, as well as commentary on what the approval may really mean to our oncology community. Each quarter new summaries on recent FDA advances in the world of oncology will be released for review.

To download the report, please fill out the form below.